Suchergebnisse - "2494G1JF75"

PubPharm (26)

1

Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination : a comparative analysis

enthalten in: AIDS (London, England) | 2019

von Venkatesh, K. | Farhad, M. | Fenton, T. | +7

2

Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288) : a prospective strategy study

enthalten in: The lancet. HIV | 2019

von Grinsztejn, B. | Hughes, M. | Ritz, J. | +80

3

Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen : a substudy of the randomised, open-label, non-inferiority SECOND-LINE study

enthalten in: The lancet. HIV | 2017

von Boyd, M. | Amin, J. | Mallon, P. | +14

CommentIn: Lancet HIV. 2017 Jun;4(6):e240. - PMID 28576610

4

Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor : An Unsettled Issue

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2016

von Karris, M. | Jain, S. | Bowman, V. | +11

5

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients : A Randomized, Multinational, Multicenter Trial

enthalten in: PloS one | 2016

von Cooper, D. | Cordery, D. | Zajdenverg, R. | +87

6

Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIV

enthalten in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA | 2015

von Hsieh, E. | Fraenkel, L. | Xia, W. | +7

7

Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial : an exploratory analysis

enthalten in: The lancet. HIV | 2015

von Boyd, M. | Moore, C. | Molina, J. | +101

CommentIn: Lancet HIV. 2015 Feb;2(2):e34-5. - PMID 26424456

8

Week 120 efficacy of tenofovir, lamivudine and lopinavir/r-based second-line antiretroviral therapy in treatment-experienced HIV patients

enthalten in: PloS one | 2015

von Han, Y. | Li, Y. | Xie, J. | +5

9

First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting

enthalten in: AIDS (London, England) | 2014

von Clumeck, N. | Mwamba, C. | Kabeya, K. | +9

10

Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection

enthalten in: Clinical drug investigation | 2014

von Moyle, G. | Hardy, H. | Farajallah, A. | +2